Hatch-Waxman Safe Harbor Murky After High Court Rejection

Law360, New York (January 14, 2013, 10:09 PM EST) -- The U.S. Supreme Court decided Monday to not hear a case over the scope of the Hatch-Waxman Act safe harbor that protects allegedly infringing conduct involving pharmaceutical patents, leaving uncertain whether the law applies to activities that take place after a drug receives government approval, attorneys say.

The safe harbor holds that otherwise-infringing conduct is legal if it is done under the requirements of federal drug laws. The justices rejected GlaxoSmithKline PLC's appeal of a Federal Circuit decision that the provision applies only to activities that...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.